ACA
SAGE

Avoro Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Avoro Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,000,000
Closed -$28.7M – 50
2020
Q1 		$28.7M Buy
+1,000,000
New +$57.9M 0.97% 24

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Avoro Capital Advisors's SAGE Position: Q2 2020 in Review

Avoro Capital Advisors sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 1,000,000 shares — an estimated $28.7M sold.

Avoro Capital Advisors first reported a position in SAGE in Q1 2020 and held it in 1 quarter. The position peaked at $28.7M in Q1 2020. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

  • Avoro Capital Advisors reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Avoro Capital Advisors sold 1,000,000 Sage Therapeutics shares in Q2 2020, an estimated $28.7M.
  • Avoro Capital Advisors first reported a position in Sage Therapeutics in Q1 2020 and held it in 1 quarter.
  • Avoro Capital Advisors's Sage Therapeutics position peaked at $28.7M in Q1 2020.
  • 217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Avoro Capital Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.